ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
말초동맥질환(PAD) 시장 규모는 2023년 37억 5,764만 달러에서 예측 기간 동안 연평균 6.64%의 CAGR로 성장하여 2030년에는 54억 6,902만 달러 규모로 성장할 것으로 예상됩니다.
말초동맥질환(PAD) 치료 수요는 주로 PAD 및 동맥경화증 유병률 증가, 비만, 당뇨병, 고혈압 유병률 증가, 노인 인구의 부담 증가, 최소침습적 시술에 대한 수요 증가 등으로 인해 예측 기간 동안 수요가 증가할 것으로 예상됩니다.
말초동맥질환(PAD) : 시장 역학
PAD 시장의 성장 촉진요인 중 하나는 동맥경화로 이어지는 PAD의 유병률 증가로, American Heart Association의 데이터(2023년)에 따르면 전 세계 평균 약 2억 명이 PAD를 앓고 있다고 합니다. 또한 Global Burden of Disease(2019년)에 따르면 2019년 40-70세 PAD 환자 수는 전 세계적으로 5,640만 명에 달합니다.
치료 유형별로는 혈관성형술용 풍선이 2023년 디바이스 부문에서 가장 큰 매출 비중을 차지했습니다.
혈관성형술 풍선 카테터는 카테터에 부착된 풍선을 침착이 진단된 동맥에 삽입합니다. 혈관성형술 풍선 카테터는 침착 또는 막힌 부위까지 신중하고 정확하게 동맥 내로 유도된 후 팽창하여 개구부를 넓히고 플라크 침착을 동맥 벽에 밀어 넣습니다. 이렇게 하면 막힌 동맥의 혈류가 회복되어 산소가 풍부한 혈액이 신체의 근육과 조직에 공급될 수 있습니다. 혈관성형술 풍선의 가장 큰 장점은 최소침습적으로 말초 동맥 질환을 치료할 수 있다는 점입니다. 혈관성형술 풍선 카테터를 이용한 말초동맥질환 치료 시 환자는 합병증이나 제한 없이 시술 후 바로 일상 생활로 복귀할 수 있습니다.
지역별로는 북미가 2023년 시장에서 가장 높은 점유율을 차지했습니다. 이는 말초 동맥 질환의 효과적인 치료에 대한 인식을 높이기 위한 정부의 노력 증가, 노인 환자의 부담 증가, 비만, 고혈압, 당뇨병의 유병률 증가, 고급 의료 시설이 이 지역에 존재하기 때문으로 분석됩니다.
세계 말초동맥질환(PAD) 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 규제 환경, 시장 규모 추정 및 예측, 각종 부문별·지역별·주요 국가별 상세 분석, 경쟁 구도, 주요 기업 프로파일 등의 정보를 전해드립니다.
목차
제1장 말초동맥질환(PAD) 시장 보고서 : 소개
조사 범위
시장 분류
시장 상정
제2장 말초동맥질환(PAD) 시장 : 주요 요약
시장 개요
제3장 경쟁 구도
제4장 규제 분석
미국
유럽
일본
중국
제5장 말초동맥질환(PAD) 시장 : 주요 요인 분석
시장 성장 촉진요인
말초동맥질환 및 동맥경화 증 이환율 상승
비만, 당뇨병, 고혈압 증가
고령화에 의한 부담 증대
최소침습 수술 수요 증가
시장 성장 억제요인과 과제
다양한 디바이스의 고비용
다양한 치료와 관련된 유해 사례
시장 기회
기술의 진보와 치료용 PAD 기기 채용 증가
제6장 말초동맥질환(PAD) 시장 : Porter's Five Forces 분석
제7장 말초동맥질환(PAD) 시장 평가
치료 유형별
디바이스
약물
최종사용자별
병원
외래 수술 센터
전문 클리닉
지역별
북미
유럽
아시아태평양
기타 지역
제8장 말초동맥질환(PAD) 시장 : 기업·제품 프로파일
Medtronic
Koninklijke Philips N.V.
B. Braun SE
Boston Scientific Corporation
BD
Terumo Corporation
Biotronik
Cordis
Abbott
AngioDynamics
Cardiovascular Systems, Inc.
Bluesail Medical Co., Ltd.
Contego Medical, Inc.
Argon Medical
REX Medical
Merck & Co., Inc.
Sanofi
Johnson and Johnson Services, Inc.
Otivio
Reflow Medical Inc.
제9장 KOL의 견해
제10장 프로젝트 접근법
제11장 DelveInsight 소개
제12장 면책사항·문의
ksm
영문 목차
영문목차
Peripheral Artery Disease (PAD) market by Treatment Type (Devices [Angioplasty Balloons, Angioplasty Stents, Plaque Modification Devices, Hemodynamic Flow Alteration Devices, and Peripheral Guidewires], and Drugs), End-User (Hospitals, Ambulatory Surgical Centers, and Specialty Clinics), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a respectable CAGR forecast till 2030 owing to the increase in the prevalence and burden of PAD & arteriosclerosis and escalating burden of the geriatric population globally
The peripheral artery disease (PAD) market was valued at USD 3,757.64 million in 2023, growing at a CAGR of 6.64% during the forecast period from 2024 to 2030 to reach USD 5,469.02 million by 2030. The demand for Peripheral Artery Disease (PAD) is primarily being boosted owing to the rising prevalence of peripheral artery disease & arteriosclerosis, the rising prevalence of obesity, diabetes, and high blood pressure, the growing burden of the elderly population, the rising demand for minimally invasive procedures, among others during the forecast period from 2024 to 2030.
Peripheral Artery Disease (PAD) Market Dynamics:
One of the main drivers for the growth of the peripheral artery disease (PAD) market is the rising prevalence of PAD disease leading to arteriosclerosis. As per data by the American Heart Association (2023), around 200 million live with peripheral artery disease globally on average. Also, as per the Global Burden of Disease (2019), there were 56.4 million prevalent cases of PAD among those aged 40 to 70, worldwide in 2019.
As per the Canadian Journal of Cardiology article (2022), the global prevalence of peripheral artery disease (PAD) was 5.6% in 2021, with higher prevalence estimates in high-income countries than in low-income countries.
Based on a recent research study, it had been reported that 75% of acute myocardial infarctions globally occurred from plaque rupture and the highest incidence of plaque rupture was observed in men above 45 years; whereas, in women, the incidence increased beyond age 50 years. PAD prevalence is similar or higher in women compared with men mainly because women form the major section of the elderly population.
Therefore, the factors stated above collectively will drive the overall Peripheral Artery Disease (PAD) market during the forecast period from 2024 to 2030.
However, the high cost of different devices, adverse events related to various treatments and others may limit their end-user base, thus acting as key constraints limiting the growth of the Peripheral Artery Disease (PAD).
Peripheral Artery Disease (PAD) market by Treatment Type (Devices [Angioplasty Balloons, Angioplasty Stents, Plaque Modification Devices, Hemodynamic Flow Alteration Devices, and Peripheral Guidewires], and Drugs), End-User (Hospitals, Ambulatory Surgical Centers, and Specialty Clinics), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the treatment type segment of the Peripheral Artery Disease (PAD) market, the angioplasty balloons in the devices category is estimated to amass a significant revenue share in the Peripheral Artery Disease (PAD) market in 2023. This can be attributed to the various properties, technical advantages, and increasing product development activities such as collaborations and regulatory approvals of angioplasty balloons during the forecast period.
Angioplasty balloon involves the insertion of a balloon attached to a catheter into an artery where the deposition has been diagnosed. The angioplasty balloon catheter is guided carefully and accurately through the artery to the deposition or blockage site and then inflated to widen the opening which pushes the plaque deposition against the wall of the artery. This allows for blood flow restoration in a blocked artery and elevation in the delivery of oxygen-rich blood to the muscles and tissues in the body. The major advantage of an angioplasty balloon is that it allows for the treatment of peripheral artery disease in a minimally invasive manner. Treatment of peripheral artery disease with the utilization of angioplasty balloon catheter ensures that the patient can return to day-to-day activities shortly after the procedure without much complications and restrictions.
The increasing technological advancements such as use of Drug-Coated Balloon (DCB) angioplasty in the treatment of PAD is going to play a crucial role in the peripheral artery disease market. In DCB, balloon coated with anti-proliferative medication and a carrier molecule (or excipient) is delivered to narrowed or blocked artery for treatment of PAD.
For example, Chocolate Touch(R) developed by TriReme Medical LLC is next generation drug-coated angioplasty balloon for the treatment of patients suffering from peripheral artery disease in the superficial femoral artery and the popliteal artery. Chocolate Touch(R) Drug-coated Balloon PTA Catheter received the US FDA approval in November 2022.
Hence, owing to all the aforementioned factors, the market will experience an increased demand for angioplasty balloons thus driving the devices category growth in the peripheral artery disease market during the forecast period from 2024 to 2030.
North America is expected to dominate the overall peripheral artery disease (PAD) market:
Among all the regions, North America is expected to account for the highest proportion of the peripheral artery disease (PAD) Market in 2023, out of all regions. This is owing to the growing government initiatives to raise awareness regarding effective treatment of peripheral artery diseases, rising burden of elderly patients, increasing prevalence of obesity, hypertension, and diabetes, and the presence of an advanced healthcare facilities in the region, thus boosting the peripheral artery disease market in North America.
As per data by the American Heart Association, 2021, PAD affected about 8.5 million U.S. adults over the age of 40, in 2021. As per the same source, African Americans are more likely to screen positive for PAD than non-Hispanic adults.
Also, according to data provided by Statistic Canada, PAD is widely prevalent in the country, affecting approximately 800,000 Canadians, every year.
The increasing prevalence of people with obesity and overweight will increase the market for peripheral artery disease as obese patients are 3-5 times more likely to develop the most severe complication of PAD. The Centers for Disease Control and Prevention (CDC) stated that in 2019, all US states and territories had an obesity rate of at least 20%, in 2019. Also as per the Government of Canada, about 1 in 4 Canadian adults are living with obesity on an average annually. Obesity rates among Canadian adults are higher in men as compared to women. The obese patients are 3-5 times more likely to develop the most severe complication of PAD called critical limb ischemia.
Furthermore in June 2022, Cardio Flow, Inc., received the U.S. Food and Drug Administration (FDA) clearance for the company's FreedomFlow(R) Peripheral Guidewire.
Additionally, in May 2022, Medtronic announced approval from the U.S. Food and Drug Administration (FDA) for the IN.PACT 018 Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter, a drug-coated balloon (DCB), indicated for the interventional treatment of peripheral arterial disease (PAD) in the superficial femoral and popliteal arteries.
Therefore, the interplay of all the aforementioned factors above would provide a conducive growth environment for the North America region in the Peripheral Artery Disease (PAD) market.
Some of the key market players operating in the peripheral artery disease (PAD) market include Medtronic, Koninklijke Philips N.V., B. Braun SE, Boston Scientific Corporation, BD, Terumo Corporation, Biotronik, Cordis, Abbott, AngioDynamics, Cardiovascular Systems, Inc., Bluesail Medical Co., Ltd., Contego Medical, Inc., Argon Medical, REX Medical, Merck & Co., Inc., Sanofi, Johnson and Johnson Services, Inc., Otivio, Reflow Medical Inc., and others.
Recent Developmental Activities in the Peripheral Artery Disease (PAD) Market:
In March 2024, BD (Becton, Dickinson and Company), a leading global medical technology company, announced enrollment of the first patient in the investigational device exemption (IDE) study, "AGILITY," which assessed the safety and effectiveness of the BD Vascular Covered Stent for the treatment of Peripheral Arterial Disease (PAD).
In October 2023, Cardio Flow, Inc., a privately held medical device company and developer of minimally invasive devices to treat peripheral artery disease (PAD), announced that it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its FreedomFlow Orbital Atherectomy Peripheral Platform.
In June 2023, Endologix announced that it received FDA approval for its Detour system to treat long, complex superficial femoropopliteal lesions. It treats complex peripheral artery disease by allowing physicians to bypass lesions in the superficial femoral artery by using stents routed through the femoral vein to restore blood flow to the leg.
Key Takeaways from the Peripheral Artery Disease (PAD) Market Report Study
Market size analysis for current Peripheral Artery Disease (PAD) market size (2023), and market forecast for 6 years (2024 to 2030)
Top key product/services developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
Key companies dominating the Peripheral Artery Disease (PAD) market
Various opportunities available for the other competitors in the Peripheral Artery Disease (PAD) market space
What are the top-performing segments in 2023? How these segments will perform in 2030?
Which are the top-performing regions and countries in the current Peripheral Artery Disease (PAD) market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for Peripheral Artery Disease (PAD) market growth in the coming future?
Target audience who can be benefited from this Peripheral Artery Disease (PAD) Market Report Study
Peripheral Artery Disease (PAD) product providers
Research organizations and consulting companies
Peripheral Artery Disease (PAD)-related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and traders dealing in Peripheral Artery Disease (PAD)
Various end-users who want to know more about the Peripheral Artery Disease (PAD) market and the latest developments in the Peripheral Artery Disease (PAD) market
Frequently Asked Questions for the Peripheral Artery Disease (PAD) Market:
1. What are Peripheral Artery Disease (PAD)?
The peripheral artery disease (PAD) is a common cardiovascular condition that is caused by plaque build-up in the arteries, resulting in restricted blood flow to the limbs. Peripheral artery disease is also linked to diabetes, aging, and high blood pressure.
2. What is the market for Peripheral Artery Disease (PAD)?
The peripheral artery disease (PAD) market was valued at USD 3,757.64 million in 2023, growing at a CAGR of 6.64% during the forecast period from 2024 to 2030 to reach USD 5,469.02 million by 2030.
3. What are the drivers for the Peripheral Artery Disease (PAD) market?
The Peripheral Artery Disease (PAD) market is slated to witness prosperity owing to the rising prevalence of peripheral artery disease and arteriosclerosis, the rising prevalence of obesity, diabetes, and high blood pressure, the growing burden of the elderly population, the rising demand for minimally invasive procedures, among others during the forecast period from 2024 to 2030.
4. Who are the key players operating in the Peripheral Artery Disease (PAD) market?
Some of the key market players operating in the peripheral artery disease (PAD) market include Medtronic, Koninklijke Philips N.V., B. Braun SE, Boston Scientific Corporation, BD, Terumo Corporation, Biotronik, Cordis, Abbott, AngioDynamics, Cardiovascular Systems, Inc., Bluesail Medical Co., Ltd., Contego Medical, Inc., Argon Medical, REX Medical, Merck & Co., Inc., Sanofi, Johnson and Johnson Services, Inc., Otivio, Reflow Medical Inc., and others.
5. Which region has the highest share in the Peripheral Artery Disease (PAD) market?
North America is expected to dominate the overall peripheral artery disease (PAD) market during the forecast period from 2024 to 2030. This is owing to the growing government initiatives to raise awareness regarding effective treatment of peripheral artery diseases, rising burden of elderly patients, increasing prevalence of obesity, hypertension, and diabetes, and the presence of an advanced healthcare facilities in the region, thus boosting the peripheral artery disease market in North America.
